|

KEYTRUDA® (pembrolizumab) 25 mg/mL Solution for Injection Clinical Trials

1 actively recruiting trial

Pipeline

Phase 1/2: 1

Top Sponsors

  • Evopoint Biosciences Inc.1

Indications

  • Other Solid Tumors1
  • Squamous Cell Carcinoma of Head and Neck1
  • Carcinoma1
  • Urothelial Carcinoma1
  • Prostate Cancer1

Other1 trial

Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.